Quantcast

Latest Rosiglitazone Stories

2008-10-30 21:00:11

PHILADELPHIA, Oct. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on AVANDIA(R) (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population. The safety of patients using our medicine is very important to us. On a continual basis, an external Hepatic Safety Board reviews any adverse event report received...

4c3eb47c3955711dbdd964a2c153b62d1
2008-10-28 08:40:00

Treatment for diabetic Americans has doubled in cost during the past six years. Last year, the bill hit an eye-popping $12.5 billion.Researchers said new, pricey drugs are driving the increase, despite a lack of evidence for the new drugs' greater benefits and safety. The study follows updated treatment advice for Type 2 diabetes that was issued last week.In the recommendations, an expert panel told doctors to use older, cheaper drugs first.Another study points to evidence that metformin, an...

2008-09-17 09:00:14

WALTHAM, Mass., Sept. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that metformin (Bristol-Myers Squibb's Glucophage, generics) is the drug of choice for the treatment of prediabetes -- a condition found in patients with an elevated risk of developing type 2 diabetes. Although primary care physicians overwhelmingly agree that treatment of prediabetes with an insulin-sensitizing agent should be...

2008-09-09 09:00:51

Novo Nordisk has presented data from a Phase III clinical study that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering, weight loss, blood pressure reduction and improvements in beta-cell functioning. The Lead 4 study was a 26-week randomized trial that compared the efficacy and safety of two different doses of liraglutide (1.2mg and 1.8mg, QD) to...

2008-09-09 09:00:09

New data analyses presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed initial combination therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor, JANUVIA(TM) (sitagliptin), and metformin provided improvements in blood sugar levels (as measured by A1C(1)) over two years of treatment and was generally well tolerated. Also presented at the meeting was a separate, new pooled analysis of 6,139 patients that showed that JANUVIA was generally...

2008-09-08 09:00:08

Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA(TM) (saxagliptin), an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions across all key measures of glucose control studied (glycosylated hemoglobin level (A1C), fasting...

2008-09-08 06:00:05

ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk , a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering (HbA1c), weight loss, blood pressure reduction and improvements in...

2008-08-29 15:00:53

A class of oral drugs used to treat type 2 diabetes may increase the risk of heart failure, two Wake Forest University School of Medicine faculty members said. Dr. Sonal Singh and Dr. Curt D. Furberg said in an editorial in the journal Heart that they strongly recommend restrictions in the use of thiazolidinediones -- the class of drugs used to control diabetes by lowering blood sugar -- and question the rationale for leaving rosiglitazone on the market. Rosiglitazone and pioglitazone are...

2008-08-13 15:01:02

A wrongful death suit was filed against GlaxoSmithKline, SmithKline Beecham, and McKesson Corporation in California Superior Court, charging that Avandia, prescribed for Type 2 Diabetes, led to heart attacks, congestive heart failure and other fatal cardiovascular injuries in seven individuals. The suit, brought by Khorrami, Pollard & Abir and Kabateck Brown Kellner, LLP, was filed on behalf of the victims' seven surviving spouses, including Los Angeles, CA, and Costa Mesa, CA,...

2008-07-14 09:00:14

PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. Food and Drug Administration (FDA) updated the prescribing information for AVANDIA(R) (rosiglitazone maleate) to include clinical findings from A Diabetes Outcome Progression Trial (ADOPT), a 4- to- 6 year head-to-head study of AVANDIA versus metformin and glyburide monotherapy in recently diagnosed type 2 diabetes patients. The percentage of patients with inadequate glucose control at five years...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related